Peter Attia Podcasts - Transcripts / Analysis

RapAdmin · December 14, 2025, 5:43am

The ketogenic diet, ketosis, and hyperbaric oxygen: weight loss, cognition, cancer, and more

AI summary:

Based on the transcript provided featuring Dom D’Agostino and Peter Attia, here is the summary and analysis.

A. Executive Summary

In this episode of The Drive, Peter Attia and Dr. Dom D’Agostino discuss the evolution of the ketogenic diet from a niche epilepsy treatment to a broad metabolic therapy for neurodegenerative diseases, cancer, and performance enhancement. D’Agostino details his background in Navy-funded research on oxygen toxicity seizures, which identified ketones as a neuroprotective fuel source superior to glucose in extreme environments.

The conversation pivots to the practical application of ketosis. D’Agostino argues against the “low protein” dogma of early ketogenic diets, advocating for high protein intake to prevent sarcopenia, especially in aging populations. He provides a critical analysis of exogenous ketones, distinguishing between first-generation esters (effective but potentially toxic or unpalatable) and modern ketone salts (balanced electrolytes, racemic mixtures).

Crucially, the dialogue covers the “metabolic therapy framework” for Glioblastoma Multiforme (GBM) and Alzheimer’s disease. D’Agostino posits that while standard of care for GBM fails, a “press-pulse” strategy targeting glucose and glutamine alongside ketosis shows promise in pre-clinical models. He concludes with an update on Hyperbaric Oxygen Therapy (HBOT) for TBI and the emerging use of ketogenic therapies for psychiatric disorders like anorexia and schizophrenia.

B. Bullet Summary

Original Research Context: D’Agostino’s interest in ketones originated from Department of Defense (DoD) research into preventing oxygen toxicity seizures in Navy SEALs using closed-circuit rebreathers.
Epilepsy Efficacy: The ketogenic diet renders ~66% of drug-resistant pediatric epilepsy patients responsive; ~33% achieve complete seizure control.
Protein Misconceptions: Standard ketogenic advice often restricts protein too severely. D’Agostino recommends higher protein (up to 1g/lb or ~2.2g/kg) to maintain muscle mass, noting that gluconeogenesis rarely kicks one out of ketosis in active individuals.
Ketone Biometrics: Blood testing remains the gold standard. Breath acetone meters have improved (e.g., Keto Air), but urine strips remain imprecise.
Carnivore Diet: Viewed clinically as a strict elimination diet beneficial for autoimmune disorders (e.g., vitiligo, RA) rather than a magic metabolic hack; it functions as a subset of the ketogenic diet.
1,3-Butanediol Risks: This alcohol-based ketone precursor can elevate liver enzymes and cause intoxication (resembling ethanol toxicity) at high doses required for therapeutic ketosis.
Racemic Ketone Salts: D’Agostino advocates for racemic salts (containing both D- and L-BHB). While D-BHB is oxidized for fuel (ATP), L-BHB acts as a signaling molecule (suppressing NLRP3 inflammasome, epigenetic modulation).
Energy Toxicity: Exogenous ketones should not raise levels significantly above 2-3 mmol/L in the presence of high glucose, as this can cause counter-regulatory insulin spikes and acidic blood pH (energy toxicity).
Alzheimer’s Mechanism: The brain exhibits glucose hypometabolism (Type 3 Diabetes) decades before cognitive decline; ketones bypass this defect as they use a different transporter (MCT) and pathway.
Cancer Strategy: For Glioblastoma, a “Press-Pulse” strategy is proposed: maintain a Glucose-Ketone Index (GKI) of 1-4 (Press) and intermittently use drugs to block glutamine/glucose (Pulse).
Lack of Cancer RCTs: Despite strong mechanistic and animal data, no Randomized Controlled Trials (RCTs) yet prove the metabolic therapy framework extends survival in human GBM patients.
Psychiatric Applications: Emerging trials (funded by the Baszucki Group) suggest ketogenic efficacy in bipolar disorder, schizophrenia, and paradoxically, anorexia nervosa (by reducing hedonic food anxiety).
Hyperbaric Oxygen (HBOT): Likely effective for acute TBI/concussion (first 48-72 hours). Evidence for chronic/old TBI is evolving, with a major DoD sham-controlled study currently underway at USF.
Actionable Supplementation: Electrolyte-bound ketone salts (e.g., Keto Start) mitigate the “keto flu” (caused by natriuresis) and provide a non-insulin-spiking fuel source.

D. Claims & Evidence Table

Claim	Evidence Provided	Assessment
Ketogenic diet controls drug-resistant epilepsy.	Cited historical Mayo Clinic data (1920s) and modern clinical stats: 2/3rds of drug-resistant pediatric patients respond.	Strong (Consensus medical fact).
1,3-Butanediol causes liver stress/intoxication.	D’Agostino’s lab data showing elevated transaminases; Attia’s anecdotal experience; mechanistic analogy to ethanol metabolism (alcohol dehydrogenase pathway).	Strong/Mechanistic (Biochemically sound).
Metabolic therapy (Keto + Drugs) extends survival in Glioblastoma (GBM).	Citations of Thomas Seyfried’s work; animal models showing tumor suppression; anecdotal case reports. Explicitly noted lack of RCTs.	Speculative/Pre-clinical (Unproven in humans via RCT).
Racemic Ketone Salts (D+L BHB) offer superior signaling.	Mechanisms cited: L-BHB persists longer in plasma and inhibits NLRP3 inflammasome/HDACs better than D-BHB (which is rapidly burned).	Strong (Supported by mechanistic literature).
Anorexia Nervosa responds to Ketogenic Diet.	Cited ongoing studies by Guido Frank (UCSD) and others; anecdotal reports of remission potentially due to altered neuropharmacology/hedonic response.	Emerging/Counter-intuitive (Needs robust trial data).
High protein intake kicks you out of ketosis.	D’Agostino refutes this based on personal data (eating ~220g protein/day) and metabolic flexibility in active individuals.	Context-Dependent (True for sedentary, false for active/metabolically flexible).

E. Actionable Insights

Prioritize Protein Over Fat Ratios: If using a ketogenic diet for body composition or longevity, do not restrict protein to 0.8g/kg. Aim for ~1g per pound of body weight (or ~2.2g/kg) to prevent muscle loss, using fat only to fill remaining caloric needs.
Mitigate “Keto Flu” with Electrolytes: The transition to ketosis causes sodium excretion (natriuresis). Supplement with sodium, potassium, and magnesium—ideally bound to ketone salts (e.g., Keto Start)—to bridge the energetic gap and prevent fatigue.
Target GKI for Therapeutic Outcomes: For managing cancer or seizures, use a Glucose Ketone Index (GKI) of 1–4. For general health/weight loss, simple carbohydrate restriction and mild ketosis (0.5–1.0 mmol/L) are sufficient.
Avoid High-Dose 1,3-Butanediol: For longevity and liver health, avoid relying on high doses of 1,3-butanediol or “jet fuel” esters that induce intoxication. Stick to ketone salts or MCT oil blends.
Acute Concussion Protocol: In the event of a concussion, immediate implementation of a ketogenic state (via exogenous ketones) combined with Hyperbaric Oxygen Therapy (if accessible) within the first 72 hours may be neuroprotective.
Use CKM or Blood Testing: Urine strips are inaccurate for long-term use. Use a Continuous Ketone Monitor (CKM) or finger-stick blood meter (e.g., Keto Mojo) to correlate specific foods with ketone inhibition.
Strategic Fasting: Instead of chronic caloric restriction, use situational fasting (e.g., during travel, high cognitive demand work, or inflammation flare-ups) to reset metabolic parameters and lower inflammation.

H. Technical Deep-Dive

1. The Biochemistry of Racemic Ketone Salts (D- vs. L-BHB)
Most commercial ketone research focuses on the D-isoform (R-3-hydroxybutyrate) because it is the primary substrate for ATP generation via the TCA cycle. However, D’Agostino highlights the utility of Racemic mixtures (DL-BHB) found in specific salts.

Metabolism: D-BHB is rapidly oxidized by tissues (heart, brain, muscle), causing plasma levels to spike and drop quickly. L-BHB is not a direct fuel substrate; it must be isomerized or metabolized slowly.
Signaling: Because L-BHB lingers in the plasma (slower clearance), it acts as a potent signaling molecule. It functions as a Histone Deacetylase (HDAC) inhibitor (increasing FoxO3a expression for stress resistance) and suppresses the NLRP3 Inflammasome (a multiprotein oligomer responsible for activation of inflammatory responses).
Conclusion: While D-BHB provides energy, the L-isoform provides the anti-inflammatory and epigenetic “drug-like” benefits of ketosis.

2. Oxygen Toxicity & Ketone Neuroprotection

Mechanism of CNS Oxygen Toxicity: High partial pressures of oxygen (Hyperoxia) increase Reactive Oxygen Species (ROS), which deactivate the enzyme Glutamic Acid Decarboxylase (GAD).
The Seizure Pathway: GAD is responsible for converting Glutamate (excitatory) into GABA (inhibitory). When ROS inhibits GAD, Glutamate accumulates and GABA depletes, leading to hyperexcitability and seizures.
Ketone Intervention: Ketosis increases the production of Adenosine (neuroprotective) and preserves GABAergic tone, effectively raising the threshold for seizures even in the presence of high oxidative stress.

I. Fact-Check Important Claims

Claim: Standard American Diet (SAD) produces a GKI of 40-50, while therapeutic ketosis is 1-4.
- Verification: Accurate. A typical non-diabetic glucose level is ~90-100 mg/dL (~5.0-5.5 mmol/L). On a SAD, ketones are ~0.1 mmol/L. GKI = Glucose/Ketone = 5.5/0.1 = 55. Therapeutic ketosis targets Glucose ~3.5 mmol/L and Ketones ~3.5 mmol/L, yielding a GKI of ~1.
Claim: No FDA indications for Hyperbaric Oxygen in TBI.
- Verification: True. There are 14 FDA-approved indications for HBOT (e.g., wound healing, decompression sickness, carbon monoxide poisoning), but Traumatic Brain Injury (TBI) is not currently one of them, making its use “off-label.”
Claim: NAD precursors (NR/NMN) have largely failed in clinical trials for longevity.
- Verification: Mostly True. While animal data is robust, human trials for NR/NMN have shown bioavailability issues and inconsistent results regarding meaningful clinical endpoints (e.g., muscle insulin sensitivity, longevity biomarkers), though some safety and minor metabolic benefits have been observed. D’Agostino suggests stabilized NAD formulations may be required.

Here is the comparison table of the specific Ketone Salt brands and their electrolyte compositions based on the available data.

Ketone Salt & Electrolyte Brand Comparison

Brand	Product	BHB Amount	BHB Form	Electrolyte Profile (Per Serving)	Key Features
Audacious Nutrition	KetoStart	10 g	Racemic (D+L)	Total Electrolytes: ~1,000 mg (Balanced mix of Sodium, Potassium, Calcium, Magnesium)	• Formulation: Designed by Dr. Dom D’Agostino. • Racemic: Contains L-BHB for signaling (anti-inflammatory) & D-BHB for fuel. • Ratio: Higher BHB load (10g) with a balanced electrolyte spread to prevent GI distress.
KetoLogic	Keto BHB	6 g	goBHB® (Typically Racemic)	Sodium: 510 mg Calcium: 260 mg Potassium: 200 mg Magnesium: 75 mg	• Sodium-Heavy: Relies heavily on sodium for the salt bond. • Lower BHB: Contains nearly half the BHB of KetoStart per serving.
Perfect Keto	Exogenous Ketone Base	11.3 g	goBHB® (Racemic)	Sodium: ~600–900 mg* Calcium: ~600 mg* Magnesium: ~350 mg* (Exacts vary by flavor)	• High Mineral Load: Often uses a split of Calcium/Magnesium/Sodium salts. • Warning: High Calcium/Magnesium content can cause GI distress in some users compared to sodium-balanced formulas.
Prüvit	Keto OS NAT	Proprietary (Est. 7–9g)	Fermented D-BHB (R-Only)	Sodium: Unlisted (Proprietary) Calcium: Unlisted (Proprietary) Magnesium: Unlisted (Proprietary)	• Proprietary Blend: Does not disclose exact electrolyte or BHB amounts. • Form: Uses “Naturally Fermented” D-BHB (Bio-identical), lacking the L-isomer found in racemic salts.
LMNT	Recharge	0 g	N/A (Electrolytes Only)	Sodium: 1,000 mg Potassium: 200 mg Magnesium: 60 mg	• Electrolyte Standard: Often used alongside ketones or for “Keto Flu” mitigation. • No Ketones: Strictly for hydration/mineral replenishment.

Analysis of Composition

Racemic vs. D-BHB:
- KetoStart (Audacious) and Perfect Keto use Racemic salts (D+L). As Dom noted, this provides the D-isoform for immediate fuel (ATP) and the L-isoform as a signaling molecule (lowering inflammation/oxidative stress) that lingers in the blood longer.
- Prüvit markets “Bio-identical” D-BHB (R-isoform only). While this mimics the ketone body produced by the liver for fuel, it misses the potential signaling benefits of the L-isoform discussed in the interview.
Electrolyte Load & “Keto Flu”:
- KetoStart and LMNT mimic a similar ~1g electrolyte load, but KetoStart attaches those electrolytes to actual Ketones (BHB).
- KetoLogic relies heavily on Sodium (510mg) and Calcium but has a lower total BHB dose (6g), which may be less effective for therapeutic ketosis compared to the 10g+ doses found in KetoStart or Perfect Keto.
Transparency:
- Audacious, KetoLogic, and LMNT are generally transparent about their “Amount Per Serving.”
- Prüvit uses a “Proprietary Blend” model, making it impossible to know if you are consuming enough BHB for a therapeutic effect or if the salt load is dangerously high for salt-sensitive individuals.

RapAdmin · December 14, 2025, 7:37am

Training for longevity: A roundtable on building strength, preventing injury, protein, & more

AI Summary:

Resistance Training, Longevity, and Muscle-Centric Medicine: Roundtable Analysis

A. Executive Summary

This roundtable discussion, hosted by Peter Attia, features three distinct experts in human performance: Dr. Gabrielle Lyon (Geriatrics and Nutritional Sciences), Mike Boyle (Strength and Conditioning Coach), and Jeff Cavaliere (Physical Therapist and founder of Athlean-X). The core thesis is that skeletal muscle is the organ of longevity, yet the majority of the population fails to engage in the resistance training necessary to maintain it. The conversation dismantles the traditional “powerlifting” dogma (squat, bench, deadlift) as the only path to strength, arguing instead for risk-managed, longevity-focused training protocols that prioritize consistency over intensity.

A significant portion of the dialogue focuses on the risk-reward trade-off of heavy spinal loading as one ages. Both Boyle and Attia argue that bilateral back squats and heavy deadlifts become orthopedically expensive for the aging individual, advocating for unilateral (single-leg) training which bypasses the “bilateral deficit” and reduces spinal compression. Dr. Lyon provides the metabolic context, defining muscle not just as a contractile tissue but as a metabolic sink for glucose and a predictor of survivability against chronic disease.

The group also addresses the crisis of youth sports specialization, agreeing that early hyper-focus on single sports leads to increased injury rates and burnout. Conversely, they argue for “sampling” (playing multiple sports) to build general athleticism. Finally, the discussion pivots to practical longevity strategies: prioritizing protein intake (minimum 100g/day), eliminating biomechanically compromised exercises (the “Iron Graveyard”), and training proprioception (balance) to prevent falls—the leading cause of catastrophic decline in the elderly.

B. Bullet Summary

Muscle as the Organ of Longevity: Skeletal muscle is the primary site for glucose disposal and metabolic regulation; its degradation (sarcopenia) is a primary driver of aging and chronic disease.
The Bilateral Deficit: Individuals often possess greater cumulative strength on single legs (left + right) than on both legs simultaneously due to neurological inhibition during bilateral lifts.
Unilateral Superiority: Single-leg training (e.g., Bulgarian split squats) stimulates high-threshold motor units and hypertrophy without the compressive spinal load of heavy back squats.
The “Iron Graveyard”: Certain exercises have a poor risk-to-reward ratio and should be abandoned, specifically upright rows (shoulder impingement risk) and unsupported chest flys (anterior capsule stress).
Nutrition Drives Composition: Leanness is achieved primarily through caloric control and nutrition, while training provides the stimulus for muscle growth; you cannot “out-train” a diet deficient in protein or excessive in calories.
Anabolic Resistance: As humans age, the efficiency of protein utilization drops. Older adults require higher protein intakes (specifically Leucine) to trigger muscle protein synthesis compared to adolescents.
Minimum Protein Threshold: A baseline of 100g of high-quality protein daily is recommended for all adults, regardless of sex, to support tissue turnover and muscle maintenance.
Youth Specialization Fallacy: Early sports specialization (pre-puberty) correlates with higher injury rates and lower long-term athletic success compared to a “sampling” period of multiple sports.
Proprioception Decay: Balance and reaction time degrade with age. Training balance with eyes closed is essential to prevent falls, as most falls occur in low-light conditions where visual feedback is absent.
Achilles Tendon Vulnerability: The Achilles is a common failure point in aging athletes; prevention requires soleus-specific stretching/rolling and ankle mobility work.
Consistency over Intensity: For the general population, the barrier to entry is often psychological (“it must be hard”). Consistency (attendance) yields better long-term results than sporadic high-intensity efforts.
Intermuscular Adipose Tissue (IMAT): IMAT (fat infiltration within the muscle) is likely a more accurate predictor of metabolic dysfunction and insulin resistance than BMI or total body fat percentage.

D. Claims & Evidence Table

Claim Made	Evidence Provided	Assessment
Bilateral Back Squats are unnecessary for hypertrophy/strength.	Boyle cites athlete data showing split-squat loads equal to front squat loads; Attia cites personal injury history and “bilateral deficit” neurology.	Strong. Supported by biomechanical research on bilateral deficit and electromyography (EMG) studies on unilateral training.
Protein intake must be at least 100g/day.	Dr. Lyon cites turnover rates of visceral tissue and the requirement of essential amino acids (specifically Leucine) to trigger mTOR in aging muscle.	Strong. Aligns with current protein research suggesting 1.2–1.6g/kg for preventing sarcopenia.
Upright Rows cause shoulder impingement.	Cavaliere cites biomechanics: internal rotation combined with elevation compresses the supraspinatus tendon against the acromion.	Strong. Widely accepted in physical therapy and orthopedics; known mechanism for subacromial impingement.
Early sports specialization leads to higher injury rates.	Boyle cites observations of overuse injuries in youth and “early succeeder” phenomenon; Lyon notes lack of injury reduction despite “advancements.”	Strong. Supported by data from the American Medical Society for Sports Medicine and pediatric orthopedics.
Eating after 6 PM causes fat gain.	Cavaliere refutes this, stating total caloric intake and protein consistency determine body composition, not meal timing.	Strong. Thermodynamics and metabolic ward studies confirm total energy balance trumps meal timing for weight loss.
IMAT is a better predictor of disease than Body Fat %.	Dr. Lyon cites clinical experience and emerging literature linking muscle fat infiltration to insulin resistance (e.g., PCOS).	Speculative/Emerging. Strong theoretical basis, but DEXA/BMI remain the clinical standard due to cost/access of MRI/CT needed to measure IMAT.

E. Actionable Insights

Switch to Unilateral Lower Body Training: Replace heavy spinal loading (back squats) with rear-foot elevated split squats (Bulgarian split squats) or reverse lunges. This maintains leg strength while sparing the lumbar spine.
Audit Your “Iron Graveyard”: Immediately stop doing Upright Rows and unsupported Dumbbell Chest Flys. Replace them with High Pulls (external rotation focus) and Floor Flys (to limit range of motion and protect the shoulder capsule).
Protein “Bookending”: Aim for a minimum of 30-50g of protein at the first and last meal of the day to ensure you hit the >100g daily floor. Focus on leucine-rich sources (animal products or fortified plant sources).
The “Eyes Closed” Balance Drill: Practice standing on one leg with eyes closed to train proprioceptive systems independent of vision. This mitigates fall risk as reaction times slow with age.
Soleus Care for Achilles Health: Perform aggressive foam rolling on the calf and specific soleus stretching (knee bent) to reduce tension on the Achilles tendon, especially if engaging in dynamic sports (pickleball, tennis).
Use the “Standing Cable Press”: If you have shoulder pain or labral issues, utilize the standing cable press. It allows for a functional pressing pattern without the fixed-path impingement of machines or bench pressing.
Gamify Fitness for Kids: Do not impose structured “sets and reps” on pre-pubescent children. Use games (e.g., card games dictating movements) to build motor patterns without the psychological burden of “training.”
Widen Your Lunge Stance: When performing lunges, step out slightly to the side (not walking a tightrope) and rotate the torso slightly over the front leg to lock the hip into a stable position.
Hydration and Fiber Audit: Following Boyle’s advice post-surgery, assess fiber intake and hydration status. Digestive health is often the silent point of failure in the 50+ demographic.

H. Technical Deep-Dive

1. The Bilateral Deficit and Neural Drive
The “Bilateral Deficit” (BLD) refers to the phenomenon where the maximal force produced by two limbs acting simultaneously is less than the sum of the forces produced by each limb acting individually ($F_{bilateral} < F_{left} + F_{right}$).

Mechanism: The primary driver is neurological inhibition. During bilateral exertion, the central nervous system (CNS) reduces neural drive to the motor units to maintain stability and protect the spine. Unilateral training bypasses this inhibition, allowing for higher motor unit recruitment in the target muscle group without the systemic fatigue or spinal shear forces associated with maximal bilateral loading.
Application: For longevity, this allows an individual to overload the quadriceps or glutes with high intensity while subjecting the lumbar vertebrae to significantly lower compressive forces.

2. Anabolic Resistance and Leucine Thresholds
Dr. Lyon references “Anabolic Resistance,” the age-related reduction in the skeletal muscle’s sensitivity to dietary amino acids and insulin.

mTORC1 Pathway: Muscle Protein Synthesis (MPS) is regulated by the mechanistic target of rapamycin complex 1 (mTORC1). In youth, insulin and low doses of amino acids easily trigger this pathway.
Aging Physiology: As tissues age, the “leucine threshold” required to trigger mTORC1 increases. While a child might trigger growth with 5g of protein, an older adult may require 2.5g to 3g of Leucine (approx. 30g of high-quality animal protein) in a single bolus to initiate the same anabolic response. This validates the recommendation for fewer, larger protein feedings rather than “grazing” on sub-threshold amounts.

3. Intermuscular Adipose Tissue (IMAT)
Distinct from subcutaneous fat (under skin) and visceral fat (around organs), IMAT is the infiltration of adipocytes between muscle fibers.

Pathology: High IMAT levels correlate strongly with insulin resistance. When fat infiltrates muscle tissue, it disrupts the insulin signaling cascade (PI3K/Akt pathway), preventing efficient glucose uptake (GLUT4 translocation). This renders the muscle—the body’s largest glucose disposal agent—metabolically inflexible, contributing to Type 2 Diabetes independent of total body mass.

I. Fact-Check Important Claims

Claim: 50% of Americans are not training or doing any kind of exercise.

Verification: True. According to CDC data (National Health Interview Survey), only ~24-28% of U.S. adults meet the combined aerobic and muscle-strengthening guidelines. Approximately 46-50% fail to meet either guideline significantly.

Claim: Kids who specialize early have higher injury rates.

Verification: True. A study published in the American Journal of Sports Medicine (2015) found that young athletes who specialized in a single sport were 81% more likely to experience overuse injuries compared to those who played multiple sports.

Claim: Upright Rows are dangerous for the shoulder.

Verification: Consensus Supported. The internal rotation required during an upright row places the greater tuberosity of the humerus in a position that reduces the subacromial space, compressing the supraspinatus tendon. Chronic repetition significantly increases the risk of subacromial impingement syndrome (SAIS).

Claim: You cannot out-train a bad diet (regarding body composition).

Verification: True. While exercise creates a caloric deficit, the compensatory mechanisms (increased appetite, non-exercise activity thermogenesis reduction) often offset exercise calories. A systematic review in Systematic Reviews (2014) confirms that exercise alone results in minimal weight loss without dietary intervention.

Alpha · December 14, 2025, 4:26pm

I think applying protein intake to weight makes no sense.
We need a more precise recommendation.

Adults (of either sex) can have a >100 lb difference in weight and some significant percentage of that difference in lean body mass (LBM).

Alternative

Shouldn’t we scale protein intake to LBM or perhaps better, desired LBM?

Essentially eat enough protein to support:

Targeted/desired lean body mass
Activity (daily calorie burn)
Demands of your training (repair and muscle growth)

LBM recommendations

One comes across recommendations taking into account LBM to aim for 1 to 2 grams of protein per kilogram or 0.5 to 1 gram per pound of LBM.

This seems like a ridiculously broad range.

Example

Male weighing 194 lbs with 16% body fat.
This yields ~31 lbs of body fat or 163 lbs LBM.

So 82 grams to 163 grams of protein per day (note: corrected from my original post).
This would give one a protein calorie range of 328 calories to 652 calories (figuring 4 calories per gram of protein)

This kind of range seems nuts.
What have I missed?

Does anyone have a more precise guideline so that we can optimize protein intake?

desertshores · December 14, 2025, 8:24pm

I couldn’t find all of the brands mentioned, but I did ask ChatGPT5 to analyze the ingredients of three popular BGB powders.

Final ranking (for real ketosis):

Nutricost Keto BHB – best ketone delivery: Racemic (D + L)
goBHB Clean Energy – mild, clean, but weak: Racemic (D + L)
Perfect Keto – too mineral-heavy, inefficient: Racemic (D + L)

C8 MCT oil: Not chiral (no D/L issue)

I am using pure C8 MCT oil. Because of my diet and eating window I am almost always in morning ketosis. I have a blood ketone test meter. I quit using it because I was always in morning ketosis.

Beth · December 14, 2025, 8:49pm

@Alpha

If you like/respect Stu Phillips, the other day I shared his response to my question if guidance for protein intake should be based on lean mass vs total body weight. I asked because in an Attia podcast, Rhonda Patrick said it was ideally on lean mass.
I did not ask him to address the question if one were morbidly obese. I imagine that answer might be slightly different.

He said:

Thanks for your thoughtful question! You’re absolutely right that older adults and those following a vegan diet, benefit from being toward the higher end of the protein range, so 1.6 g/kg is a good target.

As for whether to use total body weight or lean mass: most guidelines and research use total body weight because it’s practical and consistent. Using lean mass can make sense conceptually, but it’s not widely adopted in recommendations because lean mass measurements aren’t always available or standardized (or that good if you use a bathroom scale-type ‘body composition’ monitor). If you’re already hitting 1.6 g/kg based on lean mass, that’s great—but if you calculate based on total weight, you’ll ensure you’re meeting the evidence-based target.

Bottom line: stick with 1.6 g/kg of total body weight for simplicity and reliability.

RapAdmin · June 11, 2026, 1:28am

Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer’s disease, & more

I. Executive Summary

The core thesis of this clinical discussion centers on the absolute compartmentation of brain cholesterol homeostasis from peripheral lipid metabolism, and the profound therapeutic implications this separation holds for neurodegenerative disease prevention. Systemic apolipoprotein B (ApoB) and apolipoprotein A1 (ApoA1) particles are structurally excluded by the tight junctions of the blood-brain barrier (BBB). Consequently, the adult central nervous system relies entirely on autonomous de novo cholesterol synthesis. While peripheral tissues predominantly utilize the lathosterol pathway, adult brain cells synthesize cholesterol via the alternative Bloch pathway, utilizing desmosterol as the critical penultimate precursor.

Neurons downregulate their own energy-expensive cholesterol synthesis around age 10 to preserve metabolic adenosine triphosphate (ATP) for action potentials and synaptic transmissions, as synthesizing a single molecule of cholesterol demands over 30 molecules of ATP across a complex 37-step pathway. Post-developmental brains shift this lipid manufacturing burden to astrocytes. Astrocytes package synthesized cholesterol into apolipoprotein E (ApoE) containing high-density lipoprotein (HDL)-like particles, which are secreted into the matrosome (extracellular matrix) and subsequently cleared by neuronal low-density lipoprotein (LDL) receptors and LDL receptor-related protein 1 (LRP1).

Pathology arises when localized lipid clearance kinetics are disrupted, a state heavily driven by the inheritance of the APOE4 allele. The single amino acid substitutions characterizing the ApoE4 protein alter its confirmation and diminish its binding affinity for neuronal receptors, trapping cholesterol within the neuronal cell membrane while starving the intracellular cytosol. This membrane cholesterol overload forces amyloid precursor protein (APP) into specialized lipid rafts where beta- and gamma-secretases preferentially cleave it into neurotoxic amyloid-beta 42, rather than the benign, non-aggregating amyloid-beta 40 isoform generated by alpha-secretase under normal lipid conditions. To protect against intracellular lipid crystallization and subsequent apoptosis, distressed neurons express 24S-hydroxycholesterolase to convert excess cholesterol into the highly hydrophilic oxysterol 24S-hydroxycholesterol, which readily crosses the BBB into systemic plasma for hepatic elimination via bile acids.

Pharmacological targeting of this axis reveals distinct translational barriers and opportunities. While standard lipid-lowering therapies act exclusively in the periphery, statins cross the BBB at steady state to inhibit central HMG-CoA reductase. While major trials indicate cognitive neutrality or long-term benefit, excessive central suppression can cause acute, reversible cognitive deficits (“brain fog”), which can be mitigated by keeping plasma desmosterol levels above 0.8 to 1.0 mg/L. Ezetimibe’s glucuronidated metabolite also crosses the BBB, showing preclinical efficacy in disrupting the pathological hexokinase-1::14-3-3G protein interface to trigger autophagic clearance of aggregates. Most remarkably, novel data from the cholesteryl ester transfer protein (CETP) inhibitor obicetrapib demonstrates a robust, placebo-adjusted 20.48% reduction in plasma p-tau217 alongside significant drops in NfL and GFAP among APOE4/E4 homozygotes. This effect is achieved because systemic CETP inhibition induces hepatic overproduction of ApoA1, which crosses the BBB to structurally rescue dysfunctional ApoE4 central lipid particles.

II. Insight Bullets

Absolute Cellular Autonomy: Every individual cell in the human body possesses the evolutionary machinery to synthesize its own structural cholesterol de novo to maintain membrane integrity.
Crystallization Toxicity: Intracellular accumulation of cholesterol exceeding precise physiological thresholds triggers intracellular crystallization, inducing severe cellular toxicity and apoptosis.
Dual-Route Systemic RCT: Systemic reverse cholesterol transport (RCT) operates via a direct route (HDL transporting mass to the liver) and an indirect route (HDL transferring mass to ApoB particles for hepatic receptor clearance).
LDL as a Return Vessel: The physiological purpose of low-density lipoprotein (LDL) is to act as a transport vehicle returning peripheral cholesterol to the liver, rather than acting as a delivery mechanism to healthy cells.
Equilibrium vs. Deprivation: Aggressive pharmacological downregulation of systemic plasma LDL cholesterol reflects a shifting of systemic lipid equilibrium rather than cellular lipid deprivation.
Erythrocyte Mass Dominance: Red blood cell membranes carry a vastly greater absolute mass of structural cholesterol than all circulating systemic plasma lipoproteins combined.
Central Storage Reservoir: The human brain is the largest cholesterol reservoir in the body, retaining 20 to 25 grams of cholesterol (approximately 15% to 18% of total body stores) compared to the liver’s 3 to 5 grams.
High-Flux vs. Vault Kinetics: The liver operates as a high-flux transaction station that continuously deposits and expels cholesterol mass, whereas the brain acts as a secure vault with a lipid half-life of roughly five years.
Atherosclerosis Prerequisite: Atherosclerotic vascular disease cannot mechanically occur without the subendothelial retention and subsequent accumulation of ApoB-containing lipoproteins within the arterial wall.
Absolute BBB Exclusion: The blood-brain barrier establishes a strict mechanical barrier that prevents large systemic ApoB-containing lipoproteins from gaining entry to the central nervous system.
Fetal Independence: The fetal and developing infant brain synthesizes all required structural cholesterol independently of maternal circulation, even when infant systemic LDL cholesterol tracks as low as 30 mg/dL.
Neuronal Metabolic Shifting: At approximately age 10, human neurons completely deactivate autonomous cholesterol synthesis to conserve metabolic ATP for electrical action potentials and synaptic transmission.
Astrocyte Manufacturing: Adult brain cholesterol demands are met by astrocytes, which continuously synthesize lipids and secrete them into the matrosome (intercellular space) to feed neighboring neurons.
Brain Lipoprotein Substituting: The central nervous system utilizes Apolipoprotein E (ApoE) as its primary structural lipoprotein carrier, substituting for the systemic roles played by ApoB and ApoA1.
Buoyancy Homology: Brain-derived lipoproteins are classified as high-density lipoproteins (HDLs) based on density centrifugation, but they carry distinct copies of ApoE rather than systemic ApoA1.
Neuronal Clearance Mechanics: Interstitial lipid clearance by neurons is executed primarily by LRP1 (LDL receptor-related protein 1) and scavenger receptor B1 (SR-B1) due to their high binding affinities for ApoE.
Divergent Sterol Pathways: The human body splits final sterol synthesis into two distinct operational pathways: the systemic lathosterol pathway and the central desmosterol (Bloch) pathway.
Surrogate Plasma Markers: Circulating systemic plasma desmosterol correlates heavily with cerebrospinal fluid desmosterol concentrations, acting as an accessible surrogate marker of brain cholesterol synthesis.
Genotypic Isoform Bending: The inherited APOE genotype dictates the physical confirmation of the ApoE protein; single amino acid substitutions alter structural bending and ligand-binding kinetics.
ApoE4 Clearance Deficits: The inherited ApoE4 isoform creates a structurally compromised protein that reduces clearance kinetics at the neuronal receptor interface, inducing local cholesterol transport failure.
Amyloid Precursor Shifting: Excess cholesterol retention within the neuronal cell membrane physically shifts amyloid precursor protein (APP) into lipid rafts, accelerating toxic beta- and gamma-secretase cleavage.
Benign Peptide Production: Physiological concentrations of cell membrane cholesterol keep APP outside of lipid rafts, promoting alpha-secretase cleavage to form non-toxic amyloid-beta 40.
Oxysterol Elimination: Neurons clear toxic intracellular cholesterol accumulations by upregulating 24S-hydroxycholesterolase, converting cholesterol into the hydrophilic oxysterol 24S-hydroxycholesterol.
BBB Tunneling Dynamics: 24S-hydroxycholesterol alters cell membrane electrostatic charges, forming a microscopic transient path to diffuse across the BBB directly into systemic plasma for hepatic clearance.
Distress Biomarkers: Elevated systemic plasma concentrations of 24S-hydroxycholesterol serve as an active clinical biomarker of acute neuronal lipid overload and structural membrane stress.
Statin BBB Penetration: Both lipophilic and hydrophilic statins demonstrate steady-state blood-brain barrier penetration, actively inhibiting central HMG-CoA reductase and reducing brain sterol synthesis.
Reversible Brain Fog: Excessive statin-mediated suppression of central desmosterol can trigger acute, subjective cognitive deficits, which are rapidly reversed by dose reduction or drug class substitution.
Glucuronide BBB Crossing: Ezetimibe is metabolized into ezetimibe glucuronide, which crosses the BBB to block the pathological binding of hexokinase-1 to 14-3-3G proteins, successfully activating protective autophagy.
Lysophospholipid Transporters: Systemic omega-3 fatty acids (EPA and DHA) cross the blood-brain barrier via specialized endothelial transport receptors exclusively in the form of lysophospholipids.
Index Saturation Targets: Maintaining a red blood cell membrane omega-3 index between 8% and 10% optimizes tissue saturation and ensures adequate membrane fluidity across central and peripheral nervous systems.
Obicetrapib Biomarker Attenuation: The potent CETP inhibitor obicetrapib drastically downregulates central neurodegenerative progression biomarkers (p-tau217, NfL, GFAP), with the most profound clinical signals seen in APOE4/E4 homozygotes.
ApoA1 Rescue Cascade: Systemic CETP inhibition causes hepatic overproduction of ApoA1, which crosses the BBB to integrate into and structurally rescue dysfunctional ApoE4 brain lipid particles.

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Level A/B Evidence)

ApoB and LDL-C Reduction for Cardiovascular Protection: Implement intensive lipid-lowering therapies (statins, ezetimibe, PCSK9 inhibitors) to drive systemic ApoB levels below 60 mg/dL for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Extensive Level A meta-analyses confirm that lowering systemic ApoB dramatically reduces major adverse cardiovascular events (MACE) without increasing neurodegenerative risk or causing cellular structural deprivation.
Targeted CETP Inhibition in High-Risk Genotypes: In patients presenting with high cardiovascular risk and documented APOE4 carrier status (heterozygous or homozygous), recognize the multi-system benefits of potent Cholesteryl Ester Transfer Protein (CETP) inhibition. Data from the pre-specified phase 3 BROADWAY RCT substudy shows that 10 mg daily of obicetrapib over 52 weeks significantly attenuates the progression of Alzheimer’s disease biomarkers. Among APOE4/E4 homozygotes, obicetrapib delivered a placebo-adjusted 20.48% reduction in plasma p-tau217 (P = 0.010), alongside a 6.39% reduction in Glial Fibrillary Acidic Protein (GFAP) and a 10.49% reduction in Neurofilament Light Chain (NfL) Scheltens et al., 2025.

Experimental Tier (Level C/D Evidence)

Plasma Desmosterol Surveillance: When deploying aggressive, high-dose systemic statin therapies in patients with an APOE4 genotype or a strong family history of dementia, monitor plasma desmosterol via mass spectrometry as a non-invasive surrogate for central nervous system cholesterol synthesis Sato et al., 2012. Clinicians should titrate therapy to prevent absolute plasma desmosterol levels from dropping below 0.8 mg/L broadly, and maintain levels above 1.0 mg/L in highly vulnerable APOE4 carriers to safeguard against central over-suppression and statin-induced cognitive fog.
Optimizing the Omega-3 Index for Structural Fluidity: Supplement with high-dose, purified, third-party verified ethyl ester or phospholipid-bound Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) to achieve and maintain a verified Red Blood Cell (RBC) membrane omega-3 index between 8% and 10%. Observational cohort data establishes a strong correlation between an index greater than 8% and the retention of regional brain volume (specifically hippocampal and white matter tracts) along with improved executive processing speed, although definitive Level A prevention RCTs are lacking Satizabal et al., 2022; Harris & von Schacky, 2004.
Ezetimibe Dual-Target Utilization: Utilize ezetimibe (10 mg daily) as a foundational adjunct to low-dose statin therapy. Beyond its established Level A efficacy in blocking intestinal NPC1L1 to lower systemic ApoB, its active metabolite (ezetimibe glucuronide) crosses the blood-brain barrier in trace amounts. Large-scale clinical database mining and structural modeling show that ezetimibe disrupts the pathological 14-3-3G::Hexokinase-1 protein interface, effectively reducing toxic protein aggregation and stimulating defensive autophagy in neurodegenerative models Ganne et al., 2024.

Red Flag Zone (Safety Data Absent / Debunked Claims)

Unmonitored Statin Titration Amid Cognitive Decline: Avoid the unmonitored escalation of lipophilic statins (such as simvastatin or atorvastatin) if a patient exhibits acute, subjective cognitive decline or worsening executive dysfunction. While statins are systematically neuro-neutral, excessive local inhibition of the central Bloch pathway can impair synaptic vesicle recycling. Therapy must be adjusted or substituted with non-BBB penetrating options if desmosterol drops below critical thresholds.
Commercial Reliance on 24S-Hydroxycholesterol Assays: Do not attempt to order commercial systemic plasma 24S-hydroxycholesterol testing for routine clinical decision-making. Although highly validated in institutional research as an explicit marker of active neuronal lipid overload and membrane stress, standardized commercial assays remain completely absent for outpatient clinical deployment (“Safety Data Absent / Commercial Assay Unavailable”).
Off-Label Obicetrapib Sourcing for Isolated Dementia Prevention: Do not prescribe or seek out obicetrapib for the sole indication of preventing cognitive decline or treating asymptomatic Alzheimer’s disease. The drug is currently an investigational molecule moving through formal regulatory channels; its validated clinical endpoints are strictly restricted to peripheral ApoB reduction in patients with heterozygous familial hypercholesterolemia or established ASCVD. Long-term Phase 3 cognitive outcome data must be finalized before clinical adoption for neuro-prevention can be supported.